QA: Lexaria Bioscience Corp. in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001348362_2023_Lexaria_Bioscience_Corp.pdf

Logs

info NetIncome node detected by revenue/expenses heuristic input.sec.calculation_linkbase.edgar_model_mapping {'net_inc_node': 'OperatingIncomeLoss'}

Graph

Absolute values for 0001348362, Lexaria Bioscience Corp.

  xvar xval
0 AssetsCurrent 6,977,516
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 315,505
3 remainder_Assets 540,906
4 LiabilitiesCurrent 194,036
5 LiabilitiesNoncurrent 7,401
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 71,841
8 SellingGeneralAndAdministrativeExpense 5,724,534
9 ResearchAndDevelopmentExpense 1,842,675
10 remainder_Expenses 0
11 remainder_Revenues 255,397
12 remainder_NetIncome 0
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 7,833,927
1 Liabilities 201,437
2 Expenses 7,639,050
3 Revenues 255,397
4 StockholdersEquity 7,632,490
5 NetIncome -7,383,653
6 ComprehensiveNetIncome -7,383,653
7 BaseVar 7,964,906
8 EconomicCapitalRatio 1.43

Edgar->Model Mapping

Feature Distribution

Change over Time